More than a termination of investment agreements with investors

UTRECHT, Netherlands and CAMBRIDGE, Massachusetts, November 07, 2024 (GLOBE NEWSWIRE) — Merus NV (Nasdaq: MRUS), a company from the field of clinical and oncology, the innovative multi-specific full Antikörper (Biclonics^® and Triclonics^®) Entwickelt, what can be said by Bill Lundberg, MD, President, Chief Executive Officer, and the following investor conferences teilnehmen wird:

Guggenheim Securities Healthcare Innovation Conference (Kamingespräch): Service day, November 12 at 9:30 am. (Eastern time)
Stifel 2024 Healthcare Conference (Kamingespräch): Montag, November 18 at 3:00 PM. (Eastern time)

The webcasts of the presentations were shown on the investor site of the external website of the Verfügung gestellt. The archive presentation is always one of the best times after the sale.

Uber Merus
Merus is part of clinical oncology, the innovative, human bispezoidal and trispezoidal antibody in a very long series, which is also multiclonic^® not sin. Multicloning^® a change in industrial standard processes was restored. In clinical and clinical studies it is possible that with several brands herkömmlicher menschlicher monoclonaler Antikörper identical sind, z. B. has a longer period of immunity and a smaller immunity. For more information, please visit the Merus, X and LinkedIn websites.

Multicloning^®Biclonics^® and Triclonics^® since eingetragene Marken von Merus NV

CONTACT: Informationen für Anleger und Medien:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
(email protected)

Kathleen Farren
Merus N.V.
Assoc. Director IR/Corp Comms
617-230-4165
(email protected)